Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05357820 | A Study of AB-106 in Chinese Healthy Adult Men Evaluated the Effects of Itraconazole and Rifampicin on AB-106 PK | PHASE1 | COMPLETED | 56 | — | — | Jul 19, 2021 | Dec 3, 2021 | Nov 21, 2024 | 1 | China |
| NCT05357911 | A Study on the Effect of AB-106 on the Pharmacokinetics of Digoxin | PHASE1 | COMPLETED | 16 | — | — | Jul 13, 2021 | Dec 3, 2021 | Nov 21, 2024 | 1 | China |
Peak Plasma Concentration (Cmax)
Area under the plasma concentration versus time curve (AUC)
| Arm | Type | Description |
|---|---|---|
| Itraconazole cohort | EXPERIMENTAL | - |
| Rifampicin cohort | EXPERIMENTAL | - |
| digoxin cohort | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| AB-106, Itraconazole | DRUG | single dose AB-106 at Day1, Itraconazole QD at Day14\~Day28, single dose AB-106 at Day17 |
| AB-106, Rifampicin | DRUG | single dose AB-106 at Day1, Itraconazole QD at Day14\~Day32, single dose AB-106 at Day21 |
| AB-106, digoxin | DRUG | Period 1, single dose of 0.25mg digoxin; Period 2, Coadministrate AB-106 600mg and 0.25mg digoxin |
Inclusion Criteria: 1. The subject is willing to give written informed consent. 2. The subject is capable to communicate well with investigator and comply with comply with protocol throughout the study. 3. Aged between 18 to 55 at giving written informed consent. 4. Chinese male healthy subjects (N...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab, V503, GARDASIL |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| AstraZeneca PLC | AZN | 1 | — | Trastuzumab deruxtecan |